Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

25 Drugs in Development

25 Drugs in Development

DIGITAL CONTENT

26 NEWS #PharmaBuzz

media
26 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

25DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1073154-85-4, Pf-04554878, Vs-6063, 1345713-71-4, Defactinib (vs-6063, pf-04554878), N-methyl-4-((4-(((3-(n-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

Molecular Formula

C₂₀H₂₁F₃N₈O₃S

Molecular Weight

510.5 g/mol

InChI Key

FWLMVFUGMHIOAA-UHFFFAOYSA-N

FDA UNII

53O87HA2QU

Defactinib is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.

1 2D Structure

Defactinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide

2.1.2 InChI

InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)

2.1.3 InChI Key

FWLMVFUGMHIOAA-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

53O87HA2QU

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

2. Pf-04554878

3. Vs-6063

2.3.2 Depositor-Supplied Synonyms

1. 1073154-85-4

2. Pf-04554878

3. Vs-6063

4. 1345713-71-4

5. Defactinib (vs-6063, Pf-04554878)

6. N-methyl-4-((4-(((3-(n-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

7. N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide

8. 53o87ha2qu

9. Vs 6063

10. Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-

11. Vs6063

12. N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

13. N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide

14. Defactinib [usan:inn]

15. Unii-53o87ha2qu

16. Defactinib [usan]

17. Defactinib [inn]

18. Defactinib (usan/inn)

19. Pf 04554878

20. Defactinib [who-dd]

21. Gtpl7910

22. Schembl1627234

23. Chembl3137331

24. Bdbm418817

25. Dtxsid901025937

26. Hms3740o13

27. Amy42170

28. Bcp11299

29. Ex-a1037

30. Ex-a1049

31. Mfcd25977806

32. Nsc778364

33. Nsc781450

34. Nsc782549

35. Nsc800089

36. S7654

37. Us10450297, Example 317

38. Us10450297, Example 318

39. Akos026750300

40. Zinc103297739

41. Ccg-269780

42. Cs-3410

43. Db12282

44. Nsc-778364

45. Nsc-781450

46. Nsc-782549

47. Nsc-800089

48. Sb17060

49. Ncgc00386425-06

50. Ncgc00386425-11

51. Ac-35820

52. As-17045

53. Da-34914

54. Da-45890

55. Hy-12289

56. Ft-0706351

57. Ft-0721609

58. J3.502.756d

59. D10618

60. A887883

61. J-690021

62. Q27077009

63. 7kd

64. N-methyl-4-({4-[({3- [methyl(methylsulfonyl)amino]pyrazin-2- Yl}methyl)amino]-5- (trifluoromethyl)pyrimidin-2- Yl}amino)benzamide (317)

65. N-methyl-4-(4-((3-(n-methylmethylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)benzamide

2.4 Create Date

2009-01-19

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₁F₃N₈O₃S
Molecular Weight	510.5 g/mol
XLogP3	1.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	8
Exact Mass	510.14094222 g/mol
Monoisotopic Mass	510.14094222 g/mol
Topological Polar Surface Area	151 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	804
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1